Yin Yang 1 Promotes Antiprogrammed Cell Death-1 Resistance in Hepatocellular Carcinoma through Polypeptide N-Acetylgalactosaminyltransferase 16-Mediated Glycosylation of Programmed Death Ligand-1.

ABSTRACT: Immune checkpoint inhibitors (ICIs) are widely used for treating hepatocellular carcinoma (HCC), yet their efficacy remains limited, with suboptimal response rates. The predictive power of the current biomarker, programmed death ligand-1 (PD-L1), is limited by detection variability and glycosylation, underscoring the need for complementary biomarkers to enhance predictive accuracy. In this study, mass spectrometry was employed to identify proteomic alterations in HCC tissues from responders and nonresponders to anti-programmed cell death-1 (PD-1) therapy. Survival analysis established the role of Yin Yang 1 (YY1) in determining ICI efficacy. Coculture models of hepatoma and CD8⁺ T cells revealed the immunosuppressive function of YY1. Transcriptome sequencing identified polypepti

SUBMITTER: Lin SS 

PROVIDER: S-EPMC12658286 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature